We are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have limitations.
Location: United States, New York, Uniondale
Member count: 51-200
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | Formic Ven... | formic.vc |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 05.01.2022 | Angion Pro... | -- First patient enrolled in t... | - | - | marketscre... |
| 10.11.2019 | Angion’s k... | “There were two graft failures... | - | - | medcitynew... |
| - | Angion’s k... | Angion Biomedica announced pos... | - | - | medcitynew... |